Related references
Note: Only part of the references are listed.Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim
J. Moukharskaya et al.
SUPPORTIVE CARE IN CANCER (2016)
Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report
Cristina Romeo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
The five Ws for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)
Matteo Lambertini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base
Jeffrey J. Kirshner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and 'emergency' hematopoiesis
Athanasia D. Panopoulos et al.
CYTOKINE (2008)
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
MD Green et al.
ANNALS OF ONCOLOGY (2003)
Share Paper
